Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

Description

The overall goal of this research is to help develop a new magnetic resonance (MR) method, Quantitative Susceptibility Mapping (QSM), to improve the measurement of liver iron concentrations without the need for a liver biopsy. Measurement of liver iron is important to diagnose and treat patients who have too much iron in their bodies (iron overload). Liver iron measurements by current MRI methods (R2 and R2\*) can be inaccurate because of the effects of fat, fibrosis and other abnormalities. QSM should not be affected by these factors and should be free of these errors. In this study, MRI measurements (QSM, R2 and R2\*) of iron in patients before liver transplant will be compared with chemical analysis of iron in liver explants (livers removed from patients undergoing liver transplant). The liver explants would otherwise be discarded. Investigators expect that this study will show that the new MRI method, QSM, is superior to the current MRI methods, R2 and R2\*.

Conditions

MRI Scans

Talk to us

Study Overview

On this page

Study Details

Study overview

The overall goal of this research is to help develop a new magnetic resonance (MR) method, Quantitative Susceptibility Mapping (QSM), to improve the measurement of liver iron concentrations without the need for a liver biopsy. Measurement of liver iron is important to diagnose and treat patients who have too much iron in their bodies (iron overload). Liver iron measurements by current MRI methods (R2 and R2\*) can be inaccurate because of the effects of fat, fibrosis and other abnormalities. QSM should not be affected by these factors and should be free of these errors. In this study, MRI measurements (QSM, R2 and R2\*) of iron in patients before liver transplant will be compared with chemical analysis of iron in liver explants (livers removed from patients undergoing liver transplant). The liver explants would otherwise be discarded. Investigators expect that this study will show that the new MRI method, QSM, is superior to the current MRI methods, R2 and R2\*.

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy in Transfusional Iron Overload

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

Condition
MRI Scans
Intervention / Treatment

-

Contacts and Locations

New York

Weill Cornell Medical College, New York, New York, United States, 10021

New York

Columbia University Medical Center, New York, New York, United States, 10032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Established diagnosis of thalassemia major
  • * Treatment with deferasirox formulated as Jadenu® as the sole iron chelating therapy (ICT)
  • * Regular transfusion with records maintained in the Cornell Thalassemia Program
  • * 2 years of age or older
  • * Females who are not pregnant
  • * Men and women aged 21 years or older
  • * Able and willing to give consent
  • * No known hematological and liver disease
  • * No contraindications for MRI
  • * A history of auditory or ocular toxicity related to ICT
  • * A history of poor adherence to prescribed therapy
  • * An inability to tolerate MRI examinations
  • * Treatment for mental illness
  • * Institutionalization or imprisonment

Ages Eligible for Study

2 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Weill Medical College of Cornell University,

Gary M Brittenham, MD, PRINCIPAL_INVESTIGATOR, Columbia University

Yi Wang, PhD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Sujit S Sheth, MD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Study Record Dates

2025-07-31